Announced
Synopsis
EDB Investments agreed to invest $45m in Arcturus Therapeutics, a clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines. “The promising Phase 1/2 study results indicate that ARCT-021 could be effective as a single administration, which differentiates this investigational vaccine from many other Covid -19 vaccines in development. ARCT-021 has the potential to provide important public health benefits by greatly facilitating broad administration across multiple populations worldwide,” Professor Ooi Eng Eong, Arcturus’ Vaccine Platform member of Scientific Advisory Board.
Show Details & Financials
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.